alimera-sciences-inc-logo.jpg
Alimera Sciences Receives $20 Million From Ocumension Therapeutics
April 14, 2021 09:00 ET | Alimera Sciences, Inc.
 Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone paymentsOcumension makes a $10 million equity investment in...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021
April 09, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference
March 18, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland
March 17, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, March 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
March 11, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, March 11, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences Reports Fourth Quarter and 2020 Results
February 24, 2021 16:05 ET | Alimera Sciences, Inc.
Fourth Quarter Highlights: Consolidated Net Revenue of $13.8 Million Up 10% vs. Third Quarter of 2020 Consolidated Net Revenue Down 20% vs. Fourth Quarter of 2019 Due to COVID-19...
alimera-sciences-inc-logo.jpg
Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications
February 18, 2021 08:30 ET | Alimera Sciences, Inc.
ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update
February 17, 2021 08:30 ET | Alimera Sciences, Inc.
ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference
February 15, 2021 08:30 ET | Alimera Sciences, Inc.
ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...